Literature DB >> 9188648

A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB).

J M Strizki1, J D Turner, R G Collman, J Hoxie, F González-Scarano.   

Abstract

We used a monoclonal antibody (12G5) directed against an extracellular domain of CXCR-4 to investigate the role of this receptor in infection of immortalized lymphoid cell lines, peripheral blood mononuclear cells (PBMCs), and primary brain microglia with a dual-tropic strain of human immunodeficiency virus (HIV-1(89.6)) and a T-tropic strain (HIV-1(IIIB)). Addition of antibody 12G5 to cells prior to and during infection with HIV-1(89.6) inhibited p24 production 100- to 10,000-fold in CEMx174 and 174-CD4 cells and about 10-fold in PBMC cultures but had no activity against infection of either monocyte-derived macrophages or brain microglia. In contrast, 12G5 had little or no effect on infection of CEMx174 cells with HIV-1(IIIB) or HIV-1(HxB). To identify the region of the HIV-1(89.6) envelope that confers sensitivity to 12G5, we used chimeric molecular clones. Chimeras containing the V3 loop region of HIV-1(89.6) were inhibited by 12G5 to the same degree as wild-type HIV-1(89.6) whereas replication of those viruses containing the V3 loop of HIV-1(HxB) was not inhibited by the antibody. A similar pattern was seen in infections of a U87 glioblastoma line that coexpresses CD4 and CXCR-4. Antibody 12G5 was also able to block fusion between HeLa-CD4 cells and CEMx174 cells chronically infected with HIV-1(89.6) but had no effect on fusion mediated by cells chronically infected with HIV-1(IIIB). Taken together, these results suggest that different strains of HIV-1 may interact with different sites on CXCR-4 or may have different binding affinities for the coreceptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188648      PMCID: PMC191816          DOI: 10.1128/JVI.71.7.5678-5683.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

4.  HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.

Authors:  Y Feng; C C Broder; P E Kennedy; E A Berger
Journal:  Science       Date:  1996-05-10       Impact factor: 47.728

5.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

6.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.

Authors:  A McKnight; D Wilkinson; G Simmons; S Talbot; L Picard; M Ahuja; M Marsh; J A Hoxie; P R Clapham
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.

Authors:  J He; Y Chen; M Farzan; H Choe; A Ohagen; S Gartner; J Busciglio; X Yang; W Hofmann; W Newman; C R Mackay; J Sodroski; D Gabuzda
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

8.  Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.

Authors:  M Loetscher; T Geiser; T O'Reilly; R Zwahlen; M Baggiolini; B Moser
Journal:  J Biol Chem       Date:  1994-01-07       Impact factor: 5.157

9.  V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate.

Authors:  F M Kim; D L Kolson; J W Balliet; A Srinivasan; R G Collman
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

10.  Replication of a macrophage-tropic strain of human immunodeficiency virus type 1 (HIV-1) in a hybrid cell line, CEMx174, suggests that cellular accessory molecules are required for HIV-1 entry.

Authors:  K A Stefano; R Collman; D Kolson; J Hoxie; N Nathanson; F Gonzalez-Scarano
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more
  24 in total

1.  CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Authors:  Sven Jähnichen; Christophe Blanchetot; David Maussang; Maria Gonzalez-Pajuelo; Ken Y Chow; Leontien Bosch; Sindi De Vrieze; Benedikte Serruys; Hans Ulrichts; Wesly Vandevelde; Michael Saunders; Hans J De Haard; Dominique Schols; Rob Leurs; Peter Vanlandschoot; Theo Verrips; Martine J Smit
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Modest human immunodeficiency virus coreceptor function of CXCR3 is strongly enhanced by mimicking the CXCR4 ligand binding pocket in the CXCR3 receptor.

Authors:  Sigrid Hatse; Dana Huskens; Katrien Princen; Kurt Vermeire; Gary J Bridger; Erik De Clercq; Mette M Rosenkilde; Thue W Schwartz; Dominique Schols
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 4.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

5.  Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.

Authors:  K E Follis; M Trahey; R A LaCasse; J H Nunberg
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.

Authors:  D Schols; J A Esté; C Cabrera; E De Clercq
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells.

Authors:  Naobumi Hosogane; Zhiping Huang; Bernard A Rawlins; Xia Liu; Oheneba Boachie-Adjei; Adele L Boskey; Wei Zhu
Journal:  Int J Biochem Cell Biol       Date:  2010-03-31       Impact factor: 5.085

8.  Induction of MHC class I expression on immature thymocytes in HIV-1-infected SCID-hu Thy/Liv mice: evidence of indirect mechanisms.

Authors:  G Kovalev; K Duus; L Wang; R Lee; M Bonyhadi; D Ho; J M McCune; H Kaneshima; L Su
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

9.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

10.  Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.

Authors:  Jeremiah D Heredia; Jihye Park; Riley J Brubaker; Steven K Szymanski; Kevin S Gill; Erik Procko
Journal:  J Immunol       Date:  2018-04-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.